EnteroMedics

EnteroMedics appoints Scott A. Shikora EVP of medical affairs, CMO

Thursday, April 9, 2015

EnteroMedics, a developer of medical devices using neuroblocking therapy to treat obesity, metabolic diseases and other gastrointestinal disorders, has named Scott A. Shikora, M.D., FACS, executive vice president of medical affairs and chief medical officer of EnteroMedics, effective June 1. He will lead the company’s medical affairs, clinical and regulatory functions.

[Read More]

FDA approves VBLOC vagal blocking therapy for obesity

Friday, January 16, 2015

The FDA has approved medical device company EnteroMedics’ VBLOC vagal blocking therapy, delivered via the Maestro System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years.

[Read More]